Navigation Links
Results Of Human Trials Of Hungarian Bird-Flu Vaccine Expected Today

BUDAPEST - In what is the first promising news regarding the deadly bird flu virus, the Hungarian veterinary services department (ANTSZ) has said that a prototype //of a vaccine developed against the disease was proving effective against birds.

'The effectiveness of the prototype vaccine against the Asian H5N1 strain of bird flu is proved among poultry and so it can be used to vaccinate them. If the clinical trials are positive this prototype will serve as a basis for the production of a real vaccine,' said ANTSZ president Laszlo Bujdoso said in a statement. The vaccine was developed from isolated cells of the H5N1 strain and is effective against it. The Hungarian Prime Minister Ferenc Gyurcsany has announced that all of the country's citizens would be vaccinated for free and that the cost of this would be borne by the commercial sales of the vaccine to other countries. The results of the human trials are expected on Wednesday or Thursday.

If these results are positive, we will immediately launch the procedure for putting on the market and mass producing the vaccine,' Gyurcsany said in an interview on national radio. The government has said that it can produce 500,000 doses of the vaccine per week and estimates that 3.5 million of the country's 10.6 million people need to be vaccinated to avert the predicted pandemic. The total cost of providing free vaccines is estimated to be almost a billion Hungarian forints (4.0 million euros, 4.7 million dollars). 'If we are among the first in the world to be able to offer such a vaccine, you can imagine how many (doses) we will be able to sell,' Gyurcsany said adding that this would allow them to vaccinate their citizens free of charge.

Scientists fear that if the virus mutates, it can be easily transmitted form human to human and could trigger a worldwide pandemic. Hungary has said that since the mutated virus does not currently exist, there is no vaccine for it.
'"/>




Page: 1

Related medicine news :

1. Hormone Deficiency Results In Miscarriage
2. Breast Implants May Interfere With The Interpretation Of Mammogram Results
3. DNA Testing For More Accurate Results
4. Operating on a Beating Heart Yields Better Results For Blocked Heart Arteries
5. Intense Fight Against Polio In India Gets Results
6. Deadly Diarrhoea Vaccine – Trail Results Promising
7. Novartis MS Drug Shows Promising Results
8. Dealing With Stress Results In Better Academic Performance
9. Excess Intake of Alcohol Results in Permanent DNA Damage.
10. Study Reveals Better Results in Patients Suffering From Depression.
11. Mountain Biking Results In Serious Injuries
Post Your Comments:
Breaking Medicine Technology:Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2Hand Surgeons Take Ethics into Their Own Hands 2Hand Surgeons Take Ethics into Their Own Hands 3Hand Surgeons Take Ethics into Their Own Hands 4Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3Aurora Biofuels Breakthrough Doubles CO2 Uptake and Fuel Production 13617 1Aurora Biofuels Breakthrough Doubles CO2 Uptake and Fuel Production 13617 2Video Gamers Older Than You Think 54770 1Video Gamers Older Than You Think 54770 2Video Gamers Older Than You Think 54770 3Video Gamers Older Than You Think 54770 4 26quot 3BMed Records to Go 26quot 3B Stores Document and Image Files of Medical Facilities for Emergency Viewing 54765 1 26quot 3BMed Records to Go 26quot 3B Stores Document and Image Files of Medical Facilities for Emergency Viewing 54765 2 26quot 3BMed Records to Go 26quot 3B Stores Document and Image Files of Medical Facilities for Emergency Viewing 54765 3
Other Medicine Technology:CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 2CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 3CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 4CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 5CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 6CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 7New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 2New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 3New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 4New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 5New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 6New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 7